Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer.
Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer.
复制标题
循环肿瘤细胞中8号染色体的非整倍性与晚期胃癌患者的预后相关
DOI：
10.21147/j.issn.1000-9604.2016.06.04
复制
发表时间：
2016-12
期刊：
影响因子：
--
通讯作者：
Shen L
中科院分区：
文献类型：
--
作者：
Li Y;Zhang X;Gong J;Zhang Q;Gao J;Cao Y;Wang DD;Lin PP;Shen L
先前的研究表明，循环肿瘤细胞（CTC）中8号染色体的非整倍性与晚期胃癌（AGC）患者的治疗效果相关。在这项对同一 AGC 患者群体进行的后续研究中，我们研究了 CTC 中 8 号染色体的非整倍性是否以及如何与患者的临床预后相关。这项前瞻性研究针对 31 名新诊断 AGC 的患者进行。应用先前建立的集成消减富集（SE）和免疫染色-荧光原位杂交（iFISH）平台来识别、计数和表征CTC。在治疗前后对患者进行 CTC 定量并对其 8 号染色体非整倍性进行分析。 对 93.5% 的 AGC 患者进行了 CTC 测量，并确定了两种具有不同阈值的 CTC 亚型，即阈值每 7.5 mL ≥2 的多倍体 CTC 和阈值≥4 的多倍体加三倍体 CTC，发现它们与较差的无进展生存期 (PFS) 和总生存期 (OS) 显着相关。特别是，最初 6 周治疗后多倍体 CTC 增加 ≥10% 的患者的 PFS 和 OS 较差，而多倍体 CTC 减少 ≥10% 的患者 PFS 和 OS 有所改善。调整临床显着因素后，治疗后多倍体 CTC 增加 ≥10% 是 PFS 和 OS 的唯一独立预测因子。 CTC 的非整倍性与 AGC 患者的预后相关。治疗前后多倍体 CTC 的定量比较监测可能有助于预测预后和化疗耐药性的改善或较差。
Previous work indicated that aneuploidy of chromosome 8 in circulating tumor cells (CTCs) correlated with therapeutic efficacy for advanced gastric cancer (AGC) patients. In this follow-up study performed on the same population of AGC patients, we investigated whether and how aneuploidy of chromosome 8 in CTCs correlates with patients’ clinical prognosis. The prospective study was performed on 31 patients with newly diagnosed AGC. Previously established integrated subtraction enrichment (SE) and immunostaining-fluorescence in situ hybridization (iFISH) platform was applied to identify, enumerate and characterize CTCs. Quantification of CTCs and analysis of their aneuploidy of chromosome 8 were performed on patients before and after therapy. CTCs were measured in 93.5% of AGC patients, and two CTC subtypes with diverse threshold values were identified, multiploid CTCs with the threshold of ≥2 per 7.5 mL and multiploid plus triploid CTCs with the threshold of ≥4, which were found to significantly correlate with poor progression-free survival (PFS) and overall survival (OS). In particular, patients with ≥10% increased multiploid CTCs after an initial 6 weeks of therapy had poor PFS and OS, whereas improved PFS and OS were observed on those who had ≥10% decreased multiploid CTCs. After adjusting for clinically significant factors, ≥10% increased post-therapy multiploid CTCs was the only independent predictor of PFS and OS. Aneuploidy of CTCs correlates with prognosis of AGC patients. Quantitative comparison monitoring multiploid CTCs before and after therapy may help predict improved or inferior prognosis and chemoresistance.